Pemetrexed
證據等級: L5 | 預測適應症: 10 個
## 藥師評估報告
Pemetrexed 藥師筆記
一句話總結
Pemetrexed 為多標靶抗葉酸類抗腫瘤藥物，TxGNN 預測其對惡性胸膜間皮瘤和腹膜間皮瘤有療效，此預測已獲多個 Phase III 臨床試驗證實，為該疾病的第一線標準治療。
快速總覽
| 項目 | 內容 |
|---|---|
| 藥品名稱 | Pemetrexed (培美曲塞) |
| DrugBank ID | DB00642 |
| 台灣商品名 | 愛寧達注射劑 (Alimta)、各廠學名藥 |
| 原適應症 | 非小細胞肺癌、惡性胸膜間皮瘤 |
| 預測新適應症 | malignant peritoneal mesothelioma、pleural adenomatoid tumor、pleural mesothelioma、pleural epithelioid mesothelioma、pleural sarcomatoid mesothelioma、pleural biphasic mesothelioma、pericardium cancer、well differentiated papillary mesothelioma、lymphohistiocytoid mesothelioma、malignant mesothelioma (disease) |
| 證據等級 | L1 (多個 RCT) |
| TxGNN 預測分數 | 0.9999+ |
預測適應症詳細分析
1. malignant peritoneal mesothelioma L2 99.99% 主要分析
為什麼這個預測合理？
### 機轉連結
- 多標靶抗葉酸作用：Pemetrexed 抑制多個葉酸依賴性酵素 (DHFR、TS、GARFT)，阻斷嘌呤和嘧啶合成，對快速分裂的腫瘤細胞有效。
- 間皮瘤共同病理：胸膜和腹膜間皮瘤均起源於間皮細胞，具有相似的分子特徵，對 pemetrexed 的反應機制相似。
- 與鉑類藥物協同：Pemetrexed + cisplatin 的組合已證實對間皮瘤有效，此組合也適用於腹膜型。
臨床試驗
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT04462809 | PHASE2 | UNKNOWN | 40 | A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment ... |
| NCT02535312 | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 30 | Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients... |
| NCT00402766 | PHASE1 | COMPLETED | 19 | Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or... |
| NCT06543069 | PHASE2 | RECRUITING | 28 | A Single-Arm, Phase II Clinical Study of Sintilimab and Bevacizumab Combined Wit... |
| NCT05001880 | PHASE2 | RECRUITING | 66 | Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Witho... |
| NCT06057935 | PHASE2 | RECRUITING | 64 | ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicen... |
| NCT01353482 | PHASE1, PHASE2 | WITHDRAWN | 0 | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patien... |
| NCT00061477 | PHASE2 | COMPLETED | 48 | ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant P... |
| NCT03875144 | PHASE2 | SUSPENDED | 66 | Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Sy... |
| NCT03564691 | PHASE1 | COMPLETED | 470 | A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and... |
| NCT02029690 | PHASE1 | TERMINATED | 85 | Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 Wi... |
相關文獻
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 21160794 | 2009 | Article | World journal of gastrointesti | Malignant peritoneal mesothelioma. |
| 12057156 | 2000 | Article | Current treatment options in o | Peritoneal mesothelioma. |
| 30450291 | 2018 | Article | Translational lung cancer rese | Malignant peritoneal mesothelioma: a review. |
| 36765620 | 2023 | Article | Cancers | Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma. |
| 31287877 | 2019 | Article | Japanese journal of clinical o | Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in a... |
| 20047972 | 2010 | Article | British medical bulletin | Malignant mesothelioma. |
| 18841478 | 2008 | Article | Current treatment options in o | Peritoneal mesothelioma. |
| 23291819 | 2013 | Article | BMJ case reports | Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cispla... |
| 36518655 | 2022 | Article | Journal of surgical case repor | Malignant peritoneal mesothelioma-a diagnostic challenge. |
| 35407498 | 2022 | Article | Journal of clinical medicine | Treatment of Patients with Malignant Peritoneal Mesothelioma. |
| 33257382 | 2020 | Article | BMJ case reports | Nivolumab for malignant peritoneal mesothelioma. |
| 38142057 | 2023 | Article | BMJ case reports | Complete clinical remission of malignant peritoneal mesothelioma with systemic p... |
| 26941986 | 2016 | Article | Journal of gastrointestinal on | Diagnosis and management of patients with malignant peritoneal mesothelioma. |
| 29423664 | 2018 | Article | Annals of surgical oncology | Current Management and Future Opportunities for Peritoneal Metastases: Peritonea... |
| 28594258 | 2017 | Article | Expert review of anticancer th | First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal ... |
| 31583526 | 2020 | Article | Human cell | Establishment and characterization of a new malignant peritoneal mesothelioma ce... |
| 31417959 | 2019 | Article | Pleura and peritoneum | Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal m... |
| 38806763 | 2024 | Article | Annals of surgical oncology | Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelio... |
| 34723916 | 2022 | Article | Journal of immunotherapy (Hage | Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma... |
| 30834036 | 2019 | Article | Gastroenterology research | Malignant Peritoneal Mesothelioma Without Asbestos Exposure. |
2. pleural adenomatoid tumor L5 99.99%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
3. pleural mesothelioma L1 99.99%
臨床試驗（50 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT00386815 | PHASE2 | COMPLETED | 20 | Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant ... |
| NCT03760575 | PHASE1 | RECRUITING | 20 | Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Mali... |
| NCT02303899 | PHASE2 | COMPLETED | 22 | A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Peme... |
| NCT06097728 | PHASE3 | RECRUITING | 825 | A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (M... |
| NCT04153565 | PHASE1 | COMPLETED | 19 | A Phase Ib Clinical Study to Evaluate the Safety and Efficacy of Pembrolizumab (... |
| NCT00604461 | PHASE1, PHASE2 | TERMINATED | 13 | Phase I/II Trial of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Tr... |
| NCT00996567 | PHASE2 | COMPLETED | 22 | Phase II Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as... |
| NCT02610140 | PHASE2 | COMPLETED | 248 | A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetu... |
| NCT05660616 | PHASE2 | COMPLETED | 40 | Switch-Maintenance Gemcitabine After First-Line Chemotherapy (Pemetrexed-Platinu... |
| NCT02899299 | PHASE3 | COMPLETED | 605 | A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipili... |
| NCT04334759 | PHASE3 | COMPLETED | 214 | DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Adva... |
| NCT00969098 | N/A | UNKNOWN | 150 | Early Response Evaluation in Malignant Pleural Mesothelioma By Total Glycolytic ... |
| NCT00165503 | PHASE2 | TERMINATED | 16 | A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative In... |
| NCT03489616 | NA | UNKNOWN | 45 | Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastati... |
| NCT04462809 | PHASE2 | UNKNOWN | 40 | A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment ... |
| NCT00040625 | N/A | APPROVED_FOR_MARKETING | N/A | ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Mal... |
| NCT02535312 | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 30 | Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients... |
| NCT06416930 | PHASE2 | NOT_YET_RECRUITING | 59 | Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleura... |
| NCT01907100 | PHASE2, PHASE3 | TERMINATED | 545 | LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedan... |
| NCT01675765 | PHASE1 | COMPLETED | 60 | A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-... |
| NCT00407459 | PHASE2 | COMPLETED | 77 | Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin... |
| NCT03920839 | PHASE1 | WITHDRAWN | 0 | A Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants Wi... |
| NCT00402766 | PHASE1 | COMPLETED | 19 | Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or... |
| NCT06155279 | PHASE2 | ACTIVE_NOT_RECRUITING | 41 | Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and... |
| NCT00867711 | N/A | COMPLETED | 121 | Pharmacogenetics of Pemetrexed and Carboplatin in Malignant Pleural Mesothelioma... |
| NCT07157956 | PHASE1, PHASE2 | NOT_YET_RECRUITING | 318 | Phase I/II Clinical Study of CVL006 Combination Therapy in Advanced Solid Tumors |
| NCT00227630 | PHASE2 | COMPLETED | 59 | A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural ... |
| NCT02661659 | PHASE1 | WITHDRAWN | 0 | A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients Wi... |
| NCT05930665 | PHASE2 | RECRUITING | 38 | A Phase II, Prospective, Single Arm Trial of Cadonilimab in Combination With Bev... |
| NCT00738582 | PHASE2 | COMPLETED | 89 | An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cis... |
| NCT00651456 | PHASE2, PHASE3 | COMPLETED | 448 | A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Withou... |
| NCT00281125 | PHASE1, PHASE2 | TERMINATED | 20 | A Two-Cohort Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin... |
| NCT02347917 | PHASE1, PHASE2 | COMPLETED | 28 | A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplat... |
| NCT01064648 | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 117 | A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in ... |
| NCT07121374 | PHASE1, PHASE2 | RECRUITING | 37 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pl... |
| NCT06875076 | PHASE2 | RECRUITING | 25 | Efficacy and Safety of Ivonescimab (AK112) in Combination with Chemotherapy for ... |
| NCT03762018 | PHASE3 | COMPLETED | 401 | A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab... |
| NCT02436733 | PHASE2 | UNKNOWN | 64 | EORTC Randomized Phase II Study of Pleurectomy/ Decortication (P/D) Preceded or ... |
| NCT04843007 | N/A | COMPLETED | 199 | Alvopem® (Pemetrexed) Safety Assessment in Patients With Non-small Cell Lung Can... |
| NCT01241682 | PHASE1 | COMPLETED | 10 | Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Pa... |
| NCT00541073 | PHASE2 | COMPLETED | 60 | Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vi... |
| NCT01655225 | PHASE1 | COMPLETED | 156 | A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cance... |
| NCT00251550 | PHASE1, PHASE2 | COMPLETED | 12 | Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural M... |
| NCT04162015 | PHASE1 | ACTIVE_NOT_RECRUITING | 22 | Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable ... |
| NCT05765084 | PHASE1, PHASE2 | RECRUITING | 15 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Plat... |
| NCT03715933 | PHASE1 | RECRUITING | 321 | An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicoh... |
| NCT00942825 | PHASE2 | COMPLETED | 195 | Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as F... |
| NCT02707666 | PHASE1 | TERMINATED | 7 | A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in P... |
| NCT02899195 | PHASE2 | COMPLETED | 55 | Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durva... |
| NCT04158141 | PHASE3 | TERMINATED | 16 | Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy Wi... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 37931632 | 2023 | Article | Lancet (London, England) | Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleura... |
| 12860938 | 2003 | Article | Journal of clinical oncology : | Phase III study of pemetrexed in combination with cisplatin versus cisplatin alo... |
| 34985934 | 2022 | Article | Journal of clinical oncology : | New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. |
| 26719230 | 2016 | Article | Lancet (London, England) | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin... |
| 16807435 | 2006 | Article | Annals of oncology : official | Pemetrexed and malignant pleural mesothelioma. |
| 37068376 | 2023 | Article | Journal of clinical oncology : | Flashback Foreword: Pemetrexed and Cisplatin in Mesothelioma. |
| 17181984 | 2007 | Article | Health technology assessment ( | Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a syste... |
| 34802094 | 2022 | Article | Drug delivery and translationa | EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma. |
| 36232554 | 2022 | Article | International journal of molec | Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect ... |
| 34750557 | 2021 | Article | Nature medicine | Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survi... |
| 29508763 | 2018 | Article | The Lancet. Oncology | Novel therapies for malignant pleural mesothelioma. |
| 32156681 | 2020 | Article | ESMO open | How I treat malignant pleural mesothelioma. |
| 37661097 | 2023 | Article | Journal for immunotherapy of c | ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothe... |
| 35489694 | 2022 | Article | Journal of thoracic oncology : | BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Plati... |
| 37975977 | 2023 | Article | Current treatment options in o | Updates in Management of Malignant Pleural Mesothelioma. |
| 12860935 | 2003 | Article | Journal of clinical oncology : | Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of c... |
| 31103412 | 2019 | Article | The Lancet. Respiratory medici | Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive p... |
| 34491782 | 2022 | Article | JCO oncology practice | Management of Advanced Pleural Mesothelioma-At the Crossroads. |
| 28800871 | 2017 | Article | European journal of medicinal | Malignant Pleural Mesothelioma: State of the art and advanced cell therapy. |
| 39818191 | 2025 | Article | Respiratory investigation | Current drug therapy for pleural mesothelioma. |
4. pleural epithelioid mesothelioma L1 99.99%
臨床試驗（13 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT06097728 | PHASE3 | RECRUITING | 825 | A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (M... |
| NCT06155279 | PHASE2 | ACTIVE_NOT_RECRUITING | 41 | Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and... |
| NCT00227630 | PHASE2 | COMPLETED | 59 | A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural ... |
| NCT01064648 | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 117 | A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in ... |
| NCT07121374 | PHASE1, PHASE2 | RECRUITING | 37 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pl... |
| NCT05765084 | PHASE1, PHASE2 | RECRUITING | 15 | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Plat... |
| NCT04158141 | PHASE3 | TERMINATED | 16 | Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy Wi... |
| NCT01085630 | PHASE2 | COMPLETED | 72 | Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patie... |
| NCT03228537 | PHASE1 | ACTIVE_NOT_RECRUITING | 28 | A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Com... |
| NCT05932199 | PHASE1, PHASE2 | RECRUITING | 52 | Combination of Induction Durvalumab and Tremelimumab Alone Versus Durvalumab and... |
| NCT07234058 | PHASE2 | NOT_YET_RECRUITING | 126 | A NON-COMPARATIVE PHASE IIR TRIAL ASSESSING FIANLIMAB PLUS CEMIPLIMAB PLUS PEMET... |
| NCT00334594 | PHASE2 | COMPLETED | 153 | Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mes... |
| NCT01105390 | PHASE2 | WITHDRAWN | 0 | A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Pati... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 26719230 | 2016 | Article | Lancet (London, England) | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin... |
| 39814199 | 2025 | Article | Annals of oncology : official | A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemother... |
| 26873306 | 2016 | Article | Therapeutic advances in respir | Malignant pleural mesothelioma: an update on diagnosis and treatment options. |
| 25979846 | 2015 | Article | Cancer treatment reviews | The established and future biomarkers of malignant pleural mesothelioma. |
| 39818191 | 2025 | Article | Respiratory investigation | Current drug therapy for pleural mesothelioma. |
| 32682189 | 2020 | Article | Lung cancer (Amsterdam, Nether | Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish... |
| 30798074 | 2019 | Article | Annals of diagnostic pathology | Revisiting localized malignant mesothelioma. |
| 34750557 | 2021 | Article | Nature medicine | Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survi... |
| 30706690 | 2019 | Article | Thoracic cancer | Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin... |
| 31569615 | 2019 | Article | Cancers | In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleur... |
| 39008481 | 2024 | Article | PloS one | Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into stan... |
| 34491782 | 2022 | Article | JCO oncology practice | Management of Advanced Pleural Mesothelioma-At the Crossroads. |
| 31103412 | 2019 | Article | The Lancet. Respiratory medici | Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive p... |
| 33347735 | 2021 | Article | Diagnostic cytopathology | Malignant pleural neoplasm with both differentiation of epithelioid mesothelioma... |
| 40266436 | 2025 | Article | Current treatment options in o | Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: O... |
| 37572261 | 2023 | Article | PharmacoEconomics | Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinu... |
| 34711664 | 2021 | Article | Journal for immunotherapy of c | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pe... |
| 39624250 | 2024 | Article | JTO clinical and research repo | Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a ... |
| 33053560 | 2021 | Article | Oncology | Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant P... |
| 31386610 | 2019 | Article | Journal of clinical oncology : | Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chem... |
5. pleural sarcomatoid mesothelioma L2 99.99%
臨床試驗（8 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT00227630 | PHASE2 | COMPLETED | 59 | A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural ... |
| NCT01064648 | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 117 | A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in ... |
| NCT01085630 | PHASE2 | COMPLETED | 72 | Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patie... |
| NCT00334594 | PHASE2 | COMPLETED | 153 | Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mes... |
| NCT01105390 | PHASE2 | WITHDRAWN | 0 | A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Pati... |
| NCT02709512 | PHASE2, PHASE3 | COMPLETED | 249 | Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mes... |
| NCT03564691 | PHASE1 | COMPLETED | 470 | A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and... |
| NCT02029690 | PHASE1 | TERMINATED | 85 | Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 Wi... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 26719230 | 2016 | Article | Lancet (London, England) | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin... |
| 39818191 | 2025 | Article | Respiratory investigation | Current drug therapy for pleural mesothelioma. |
| 30798074 | 2019 | Article | Annals of diagnostic pathology | Revisiting localized malignant mesothelioma. |
| 28197626 | 2017 | Article | International journal of oncol | Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. |
| 31569615 | 2019 | Article | Cancers | In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleur... |
| 38204668 | 2023 | Article | JTCVS open | Extended pleurectomy/decortication and hyperthermic intraoperative intrapleural ... |
| 39624250 | 2024 | Article | JTO clinical and research repo | Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a ... |
| 31386610 | 2019 | Article | Journal of clinical oncology : | Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chem... |
| 34711664 | 2021 | Article | Journal for immunotherapy of c | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pe... |
| 35461395 | 2022 | Article | Virchows Archiv : an internati | Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleur... |
| 33053560 | 2021 | Article | Oncology | Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant P... |
| 34823894 | 2021 | Article | Lung cancer (Amsterdam, Nether | Treatment patterns and outcomes for patients with malignant pleural mesothelioma... |
| 21651743 | 2012 | Article | The clinical respiratory journ | Pemetrexed in malignant pleural mesothelioma and the clinical outcome. |
| 26538423 | 2015 | Article | The Lancet. Oncology | Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mes... |
| 24507393 | 2013 | Article | Zhonghua jie he he hu xi za zh | [Clinicopathological characteristics and prognosis of malignant pleural mesothel... |
| 24492162 | 2014 | Article | Clinical lung cancer | Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive pati... |
| 31455014 | 2019 | Article | International journal of molec | Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Me... |
| 26577445 | 2016 | Article | International journal of clini | Trimodality strategy for treating malignant pleural mesothelioma: results of a f... |
| 34589965 | 2020 | Article | JTO clinical and research repo | Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patien... |
| 20085865 | 2010 | Article | Clinical lung cancer | Carboplatin plus pemetrexed as first-line treatment of patients with malignant p... |
6. pleural biphasic mesothelioma L1 99.99%
臨床試驗（5 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT06155279 | PHASE2 | ACTIVE_NOT_RECRUITING | 41 | Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and... |
| NCT04158141 | PHASE3 | TERMINATED | 16 | Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy Wi... |
| NCT03228537 | PHASE1 | ACTIVE_NOT_RECRUITING | 28 | A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Com... |
| NCT02709512 | PHASE2, PHASE3 | COMPLETED | 249 | Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mes... |
| NCT03564691 | PHASE1 | COMPLETED | 470 | A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 25979846 | 2015 | Article | Cancer treatment reviews | The established and future biomarkers of malignant pleural mesothelioma. |
| 39818191 | 2025 | Article | Respiratory investigation | Current drug therapy for pleural mesothelioma. |
| 28197626 | 2017 | Article | International journal of oncol | Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. |
| 31569615 | 2019 | Article | Cancers | In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleur... |
| 39624250 | 2024 | Article | JTO clinical and research repo | Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a ... |
| 31386610 | 2019 | Article | Journal of clinical oncology : | Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chem... |
| 34711664 | 2021 | Article | Journal for immunotherapy of c | JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pe... |
| 40441085 | 2025 | Article | Pathology, research and practi | Cisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignan... |
| 33053560 | 2021 | Article | Oncology | Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant P... |
| 35461395 | 2022 | Article | Virchows Archiv : an internati | Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleur... |
| 34823894 | 2021 | Article | Lung cancer (Amsterdam, Nether | Treatment patterns and outcomes for patients with malignant pleural mesothelioma... |
| 34063225 | 2021 | Article | Cancers | Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant... |
| 26715491 | 2015 | Article | Radiation oncology (London, En | Long-term results in malignant pleural mesothelioma treated with neoadjuvant che... |
| 28892431 | 2017 | Article | Journal of clinical oncology : | Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothel... |
| 24507393 | 2013 | Article | Zhonghua jie he he hu xi za zh | [Clinicopathological characteristics and prognosis of malignant pleural mesothel... |
| 24989332 | 2014 | Article | Cancer | Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetre... |
| 26577445 | 2016 | Article | International journal of clini | Trimodality strategy for treating malignant pleural mesothelioma: results of a f... |
| 22261805 | 2012 | Article | Clinical cancer research : an | CD26 overexpression is associated with prolonged survival and enhanced chemosens... |
| 34589965 | 2020 | Article | JTO clinical and research repo | Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patien... |
| 23714495 | 2013 | Article | American Society of Clinical O | Peritoneal mesothelioma: the site of origin matters. |
7. pericardium cancer L2 99.99%
臨床試驗（3 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT04462809 | PHASE2 | UNKNOWN | 40 | A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment ... |
| NCT02662504 | PHASE2 | COMPLETED | 6 | Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimo... |
| NCT01590160 | PHASE1, PHASE2 | COMPLETED | 27 | A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Mali... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 17936406 | 2008 | Article | Lung cancer (Amsterdam, Nether | Primary pericardial mesothelioma. |
| 18473795 | 2008 | Article | Current medicinal chemistry | Molecular targets and targeted therapies for malignant mesothelioma. |
| 30450660 | 2019 | Article | Journal of clinical ultrasound | Localized primary malignant pericardial mesothelioma. |
| 30594459 | 2019 | Article | Clinical lung cancer | Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Revie... |
| 22104079 | 2012 | Article | Cancer treatment reviews | Diffuse malignant peritoneal mesothelioma--an update on treatment. |
| 32787452 | 2020 | Article | Journal of investigative medic | An Unpleasant Surprise: Abdominal Presentation of Malignant Mesothelioma. |
| 39727229 | 2025 | Article | Thoracic cancer | EGFR, TP53, and CUL3 Triple Mutation in Non-Small Cell Lung Cancer and its Poten... |
| 20035722 | 2010 | Article | Biochemical and biophysical re | An epigenetic mechanism for capecitabine resistance in mesothelioma. |
| 37248188 | 2023 | Article | Zhonghua lao dong wei sheng zh | [A case of malignant peritoneal mesothelioma]. |
| 15955137 | 2005 | Article | Respirology (Carlton, Vic.) | Advances in the diagnosis, evaluation, and management of malignant pleural mesot... |
| 35117552 | 2020 | Article | Translational cancer research | Combined immune checkpoint inhibitor and chemotherapy is effective in a patient ... |
| 36602504 | 2022 | Article | The heart surgery forum | A Rare Case of Primary Malignant Pericardial Mesothelioma Diagnosed with Pericar... |
| 26281826 | 2015 | Article | International journal of radia | Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesot... |
| 17762349 | 2007 | Article | Journal of thoracic oncology : | Report of a case of pericardial mesothelioma with liver metastases responding we... |
| 34645482 | 2021 | Article | Journal of cardiothoracic surg | Malignant primary pericardial mesothelioma presenting as effusive constrictive p... |
| 22352060 | 2011 | Article | Nihon Kokyuki Gakkai zasshi = | [An autopsied case of primary malignant pericardial mesothelioma diagnosed antem... |
| 18280176 | 2008 | Article | European journal of cardio-tho | Pericardial malignant mesothelioma: a latent complication of radiotherapy? |
| 21916183 | 2011 | Article | Kyobu geka. The Japanese journ | [Current status of surgical treatment for malignant pleural mesothelioma]. |
| 24878161 | 2014 | Article | Revue des maladies respiratoir | [Intrapericardial lung cancer metastases: Is a curative approach feasible?]. |
| 17590095 | 2007 | Article | Anales de medicina interna (Ma | [Peritoneal mesothelioma: an inusual clinical presentation in a patient without ... |
8. well differentiated papillary mesothelioma L4 99.99%
相關文獻（6 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 23964112 | 2013 | Article | Japanese journal of clinical o | Therapeutic strategies for well-differentiated papillary mesothelioma of the per... |
| 28435764 | 2017 | Article | Cureus | A Case of Well-Differentiated Papillary Mesothelioma of the Male Peritoneum: Suc... |
| 23714495 | 2013 | Article | American Society of Clinical O | Peritoneal mesothelioma: the site of origin matters. |
| 38806763 | 2024 | Article | Annals of surgical oncology | Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelio... |
| 26210689 | 2015 | Article | Annales de pathologie | [Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papill... |
| 29147606 | 2017 | Article | Oncoimmunology | Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expressio... |
9. lymphohistiocytoid mesothelioma L5 99.99%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
10. iminoglycinuria L5 99.97%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
台灣上市資訊
| 許可證字號 | 商品名 | 適應症 | 狀態 |
|---|---|---|---|
| 衛部藥陸輸字第000892號 | 培美曲塞二鈉 (原料藥) | 抗腫瘤藥 | 已註銷 |
| 衛部菌疫輸字第001025號 | 吉舒達注射劑 (Keytruda) | 非小細胞肺癌 (與 pemetrexed 併用)、惡性胸膜間皮瘤 (與 pemetrexed 併用) | 有效 |
注意：台灣已核准 pembrolizumab 與 pemetrexed 及含鉑化療併用，作為無法切除之晚期或轉移性惡性胸膜間皮瘤的第一線治療。
安全性考量
重要警語
- 骨髓抑制：嗜中性球低下、血小板低下為劑量限制毒性
- 腎毒性：需監測腎功能，腎功能不全需調整劑量
- 皮膚毒性：皮疹常見，可能需要類固醇預防
必要補充治療
| 補充劑 | 目的 | 給予方式 |
|---|---|---|
| 葉酸 | 減少血液毒性 | 每日口服 350-1000 mcg |
| 維生素 B12 | 減少血液毒性 | 每 9 週肌肉注射 1000 mcg |
| Dexamethasone | 減少皮膚毒性 | 治療前後給予 |
藥物交互作用
| 交互作用藥物 | 影響說明 |
|---|---|
| NSAIDs | 可能增加 pemetrexed 毒性，需停藥 |
| 腎毒性藥物 | 增加腎臟損傷風險 |
| 肝素類 | 增加出血風險 |
特殊族群
- 腎功能不全 (CrCl < 45 mL/min)：不建議使用
- 肝功能不全：輕度可使用，中重度需謹慎
- 孕婦：禁忌使用
- 老年人：需密切監測腎功能
結論與下一步
整體評估
Pemetrexed 對惡性間皮瘤 (包括腹膜型) 的預測已獲堅實證據支持：
- 證據等級最高 (L1)：多個臨床試驗證實療效
- 標準治療地位確立：Pemetrexed + cisplatin 為間皮瘤第一線標準治療
- 免疫療法組合：與 PD-1 抑制劑併用已獲台灣核准
- 適應症延伸：胸膜和腹膜間皮瘤的治療原則相似
目前臨床定位
| 間皮瘤類型 | Pemetrexed 治療角色 |
|---|---|
| 惡性胸膜間皮瘤 | 第一線標準治療 (+ cisplatin +/- pembrolizumab) |
| 惡性腹膜間皮瘤 | 第一線化療選項 (+ cisplatin) |
建議行動
- 腹膜間皮瘤適應症申請：若尚未正式核准，可考慮申請適應症擴展
- 臨床經驗累積：收集實際臨床數據支持療效
- 關注免疫療法組合：pembrolizumab + pemetrexed 組合可能也適用於腹膜型
本報告由 TxGNN 預測系統生成，僅供研究參考，不構成醫療建議。
相關藥物報告
- Felodipine - 證據等級 L5
- Iodixanol - 證據等級 L5
- Ferrous Gluconate - 證據等級 L5
- Clomipramine - 證據等級 L5
- Gefitinib - 證據等級 L5
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
引用本報告
如需引用本報告，請使用以下格式：
APA 格式：
TwTxGNN. (2026). Pemetrexed老藥新用驗證報告. https://twtxgnn.yao.care/drugs/pemetrexed/
BibTeX 格式：
@misc{twtxgnn_pemetrexed,
title = {Pemetrexed老藥新用驗證報告},
author = {TwTxGNN Team},
year = {2026},
url = {https://twtxgnn.yao.care/drugs/pemetrexed/}
}
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。